In a multicenter randomized controlled trial (RCT), the use of viable cryopreserved placental membrane (vCPM) for chronic diabetic foot ulcers (DFUs) resulted in a higher proportion of wound closure in comparison to good wound care: 62% versus 21% (p < 0.01). However, patients in RCTs are not representative of daily physician practice. Healthcare databases serve as a valuable tool to evaluate therapy effectiveness and to supplement evidence from RCTs. The objective of this study was to evaluate the effectiveness of vCPM for DFU management using Net Health's WoundExpertV R electronic health records (EHR). The primary endpoint was the proportion of DFUs that achieved complete closure. Other endpoints included time and number of grafts to closure, probability of wound closure by week 12, and the number of wound-related infections and amputations. De-identified EHR data for 360 patients with 441 wounds treated with vCPM were extracted from the database. Average patient age was 63.7 years with a mean wound size of 5.1 cm 2 and an average wound duration of 102 days prior to vCPM treatment. For evaluation of clinical outcomes, 350 DFUs larger than 0.25 cm 2 at baseline were analyzed. Closure at the end of treatment was achieved in 59.4% of wounds with a median treatment duration of 42.0 days and 4 applications of vCPM. The probability of wound closure at week 12 was 71%, and the number of amputations and wound-related infections was 13 (3.0%) and 9 (2.0%), respectively. Data also demonstrated a correlation between wound size and closure rate as well as a correlation between > 50% wound area reduction by week 4 and wound closure by week 12. The results of this study mirror previous RCT efficacy data, supporting the benefits of vCPM for DFU management. These results can also influence policy and treatment decisions regarding advanced vCPM technology.
ABSTRACT
In a multicenter randomized controlled trial (RCT), the use of viable cryopreserved placental membrane (vCPM) for chronic diabetic foot ulcers (DFUs) resulted in a higher proportion of wound closure in comparison to good wound care: 62% versus 21% (p < 0.01). However, patients in RCTs are not representative of daily physician practice. Healthcare databases serve as a valuable tool to evaluate therapy effectiveness and to supplement evidence from RCTs. The objective of this study was to evaluate the effectiveness of vCPM for DFU management using Net Health's WoundExpertV R electronic health records (EHR). The primary endpoint was the proportion of DFUs that achieved complete closure. Other endpoints included time and number of grafts to closure, probability of wound closure by week 12, and the number of wound-related infections and amputations. De-identified EHR data for 360 patients with 441 wounds treated with vCPM were extracted from the database. Average patient age was 63.7 years with a mean wound size of 5.1 cm 2 and an average wound duration of 102 days prior to vCPM treatment. For evaluation of clinical outcomes, 350 DFUs larger than 0.25 cm 2 at baseline were analyzed. Closure at the end of treatment was achieved in 59.4% of wounds with a median treatment duration of 42.0 days and 4 applications of vCPM. The probability of wound closure at week 12 was 71%, and the number of amputations and wound-related infections was 13 (3.0%) and 9 (2.0%), respectively. Data also demonstrated a correlation between wound size and closure rate as well as a correlation between > 50% wound area reduction by week 4 and wound closure by week 12. The results of this study mirror previous RCT efficacy data, supporting the benefits of vCPM for DFU management. These results can also influence policy and treatment decisions regarding advanced vCPM technology.
Diabetic foot ulcers (DFUs) are the most common and serious complication of diabetes mellitus (DM) in the lower extremity and are a substantial financial burden on healthcare systems with approximately $9-13 billion annual spending on their treatment in the United States. 1, 2 Complications of DM and other comorbidities negatively impact wound healing, which lead to the development of chronic DFUs, defined as ulcers that fail to progress through normal phases of healing in a timely manner and remain open for a prolonged period of time.
2 Chronic DFUs negatively impact patient quality of life (QoL) and increase the risk of infection, amputation, and death.
3 DFU duration is also an independent risk factor for foot infections, which are associated with a 55-times greater risk of hospitalization and a 155-times greater risk of amputation. Ulceration precedes 85% of lower extremity amputations. [4] [5] [6] Forty-five percent, 47% and 55% 5-year mortality rates are reported for patients with neuropathic ulcers, ischemic ulcers, and amputations, respectively. 4 Diabetesrelated ulcerations and amputations have 5-year mortality rates comparable to colon cancer and higher than prostate and breast cancer. 4, 5 Accumulated data shows that DFUs are associated with dramatic negative impacts on patient QoL and on social, economic, and healthcare systems.
Treatment of DFUs remains a challenge for physicians. Proper wound care starts with thorough patient and wound assessment followed by good wound care (GWC). GWC includes debridement, infection control, moist dressings, and offloading of high pressure areas. 7 However, with GWC alone, approximately 70% of DFUs remain unhealed after 20 weeks of treatment. 8 Diabetic patients with advanced age and underlying comorbidities such as peripheral neuropathy, ischemia, and peripheral arterial disease (PAD), have a higher risk for GWC failure. These high-risk patients have impaired wound healing and require advanced treatments that can potentially promote wound closure. 9 Cellular and acellular matrices (aka skin substitutes) are a large, diverse group of advanced wound care products (AWCP) with the potential to support natural wound healing processes. These products are typically used in adjunct to GWC when a patient has failed GWC alone. Examples of AWCPs include bioengineered living cellular and dermal constructs, skin allografts, and a broad variety of animalderived collagen matrices. 10, 11 Recently, human placental membranes have been added to the growing list of AWCPs.
Placental membranes have a long history of use for burns and chronic wound management; however, placental products have only recently become commercially available. [12] [13] [14] Placental membranes have anti-inflammatory, antimicrobial, anti-fibrotic, and angiogenic properties that are supportive of the natural process of wound healing. 15 These properties are attributed to the collagen-rich extracellular matrix, bioactive factors, and viable cells, including mesenchymal stem cells that are present in the native placental tissue. 15, 16 Previously, a proprietary tissue processing method resulting in viable cryopreserved placental membrane (vCPM) has been reported. This method allows vCPM to retain components and properties of fresh placental tissue. 16, 17 Benefits of vCPM for management of chronic DFUs, including complex wounds with exposed bone or tendon, have been demonstrated in clinical studies. 18, 19 In a multicenter, randomized, controlled clinical trial, vCPM application to chronic DFUs resulted in a significantly higher proportion of wound closure by 12 weeks compared to GWC (62% vs. 21%), shorter median time to closure (42 days vs. 69.5 days), and fewer wound-related infections (18.0% vs. 36.2%). 20 Although RCTs remain the gold standard to determine treatment efficacy, RCT results may not accurately reflect the effectiveness of therapies in real world practice. Results in effectiveness studies may differ from results observed in tightly controlled experimental conditions of an efficacy study, as broader populations of patients and clinicians have access to products. Nonrandomized studies using secondary databases and registries offer an alternative approach to assess the effectiveness of therapies relevant to daily physician practice. In this study, we evaluated the effectiveness of vCPM for the management of DFUs using Net Health's WoundExpert EHR database (NetHealth, Pittsburgh, PA).
MATERIALS AND METHODS

Study design and data collection
A retrospective analysis evaluating the effectiveness of vCPM (Grafix PRIME and Grafix CORE, Osiris Therapeutics, Inc., Columbia, MD) for treatment of DFUs was performed using the WoundExpert EHR database. 21 Data from 58 wound care centers that utilize WoundExpert were analyzed in this study. All treatment records for patients with DFUs who received applications of vCPM from July 1, 2012 through June 30, 2016 were extracted from the database and de-identified, consistent with the terms and conditions outlined in the Health Insurance Portability and Accountability Act of 1996 (HIPAA). All DFUs located on the foot, toe, heel, metatarsal head, toe web space, toe amputation site, or transmetatarsal amputation site were included. A small number of wounds that received alternative skin substitute application received concurrent alternative therapy with the first application of vCPM, and wounds lacking baseline or followup wound area measurements were excluded. Wounds with a surface area 0.25 cm 2 were excluded from analyses of wound closure and closure-related outcomes.
The primary endpoint was the proportion of DFUs that achieved complete closure at the end of treatment. Wounds were considered closed or healed based on "healed" or "resolved" recorded in the database for the final wound status. Analyses of wound closure, time to closure, number of graft applications, and proportion of wounds with-50% area reduction by week 4 for wounds of different sizes were also performed.
Statistical analysis
Descriptive data are expressed using sample means and medians for continuous variables. For population means, 95% confidence intervals (CI) calculated based on Student's t distribution are provided. Confidence intervals for population medians are calculated using the nonparametric bootstrap. 22 For categorical variables, sample percentages are provided with 95% CIs calculated using the ClopperPearson method. 23 The proportion of wounds closed by week 12, week 24, and by the end of treatment, as well as time to wound closure and number of applications, are presented. Probability of wound closure was calculated by Kaplan-Meier. 24 Wound categorical factors were analyzed using the v 2 test. A test for the association between wound area reduction of 50% by week 4 and complete closure by week 12 was carried out using Fisher's exact test. 25 
RESULTS
Patient demographics and baseline wound characteristics
Three hundred sixty patients with 441 wounds treated with vCPM were evaluated and analyzed. The majority of patients were men (75%), the mean age was 63.7 years old, and 50% of patients by age ( 65 years old) were Medicare patients. Race was not consistently reported in the database and, therefore, was not included in the demographics table. Seventy six percent of patients had type II DM, and 53% had hypertension. Only 31.4% of patients had neuropathy recorded in EHR. Almost 90% of patients had multiple wounds documented in their medical histories during the 4-year period (July 2012 until June 2016), including DFUs and wounds of other etiologies. Approximately 50% of patients received treatment for more than 6 wounds, and 5% of patients received treatment for more than 20 wounds. However, in approximately 75% of patients, only one DFU per patient was treated with vCPM. The mean wound size was 5.1 cm 2 with 3.9 mm depth, and the mean wound duration was 102 days prior to treatment. Thirty percent of wounds were larger than 3 cm 2 , and 15% were complex wounds with exposed bone or tendon. One half of treated wounds were located on a toe or metatarsal head. The mean vCPM treatment duration was 89.3 (median 56.0) days. Complete lists of patient demographics and baseline wound characteristics are presented in Tables 1 and 2 , respectively. The median time interval between first patient visits and vCPM treatments was calculated using the data available in EHR. More than 70% of DFU patients had at least 28 days between the date of their first visit and the start of treatment with vCPM. This median time interval was calculated to be 51 days.
Wound closure
Wounds with a baseline size smaller or equal to 0.25 cm 2 were excluded from assessment of wound closure. Three hundred fifty wounds with sizes 0.25 cm 2 were analyzed, and 59.4% of those wounds achieved complete wound closure at the end of treatment, with a median time to closure of 42.0 days and a median of 4 vCPM applications. The probability of wound closure at week 12 as calculated by Kaplan-Meier method was 71% (Table 3 and Figure 1) .
A subanalysis showed a decrease in the proportion of closed wounds as wound size increased. For wounds between 0.25 cm 2 and 2 cm 2 , 72.3% achieved complete wound closure, with a median time to closure of 21 days and 4 vCPM applications. However, for wounds larger (Table 4) .
One hundred forty-two wounds did not achieve complete closure at the end of treatment. However, 96 out of 142 (67.6%) wounds that did not close had a reduction in size by the end of treatment. Among wounds that did not close, only 13 out of 142 wounds (9.1%) increased in size by 50% or more (Table 3) .
Amputations and wound-related infections
Among the 360 patients used for safety outcome assessments, 13 amputations (2.9%) and nine patients (2.0%) with wound infection were recorded for vCPM-treated patients (Table 3) .
Correlation between wound area reduction and closure
An analysis of the association between 50% wound area reduction by week 4 and closure by week 12 for the 350 (Table 5) showed that if a patient had a 50% reduction by week 4, the probability of closure by week 12 was estimated to be 77.8% (95% CI 70.78-83.89). If a patient did not show such reduction, the probability of closure by week 12 was estimated to be 22.5% (95% CI 16.6-29.5). This difference is highly significant (p < 10 215 ).
DISCUSSION
The primary goal of this study was to evaluate the use of vCPM for DFU management in a real-world setting using the WoundExpert database (Net Health). WoundExpert V R is a certified system representing the largest independent source of chronic wound data in the industry and gives wound care providers the tools to monitor and enhance their patient and wound care facility performance. 21 Data for all patients who received at least one vCPM application for DFU treatment from July 1, 2012 through June 30, 2016 were extracted from participating facilities using the WoundExpert EHR.
The results of this retrospective cohort study are similar to retrospective cohort studies and prospective RCTs in patients with DFUs. [18] [19] [20] Almost 60% of DFUs achieved closure with a median time to closure of 42.0 days with a median of 4 applications of vCPM. The probability of wound closure at week 12 as calculated by Kaplan-Meier method was 71% (Table 3 and Figure 1) .
A subanalysis of clinical outcomes confirms that the ulcer area is a critical parameter to predict the rate of ulcer closure. 26 Table 4 summarizes closure rates by wound size and shows an inverse relationship between the DFU size and the proportion of closed wounds. We included some small ulcers in this analysis (> 0.25 cm We also included older patients with more severe ulcers, PAD, and end-stage renal disease (ESRD) who would usually be excluded from RCTs. Further, approximately 15% of patients treated with vCPM had complex ulcers with exposed bone (7.7%), tendon, or joint capsule (7.0%). RCTs often enroll Wagner 1 and 2 ulcers that are full thickness without exposure of deeper structures (Table 2 ). Despite including high risk patients with more complex ulcers, [30] [31] [32] the results of this study were similar to the RCT with 59.4% versus 62% wound closure rates, respectively, and approximately a 70% probability of wound closure in both studies ( Table 6 ).
The real-world population of DFU patients treated with vCPM in the database are older and sicker, with larger and more complex (exposed bone/tendon) wounds than the patients and wounds treated in the RCT. The mean age of patients was 63.7 years in the database versus 55.5 years reported in the RCT, and 50% of patients were Medicare patients ( 65 years old) compared to 22% of such patients in the RCT (Tables 1 and 6 ). Patients in this study had significant comorbidities (renal failure/dialysis, PAD, Charcot) that were excluded from the RCT. In the WoundExpert V R database, wounds were larger with a mean size of 5.1 cm 2 versus 3.4 cm 2 in the RCT (Tables 2 and  6 ). Notably, the mean size of the DFUs in this study is in line with the typical DFU size seen in daily practice. 33 Approximately 15% of vCPM-treated DFUs were complex with exposed bone (7.7%), tendon, or joint capsule (7.0%), whereas in the vCPM RCT, complex DFUs were excluded (Table 2 ). Wound closure rates at the end of the treatment and the probability of closure in this study and the RCT were found to be similar: 59.4% versus 62%, and the probability of wound closure was around 70% for both studies (Table 6 ). Thus, we were able to demonstrate that vCPM treatment outcomes for chronic DFUs in the real-world setting mirror outcomes of the multicenter RCT. Although there was no standardized treatment algorithm across all wound care centers in this study, a wound care provider typically applies GWC at the first visit. If the wound does not respond to GWC in the first 4 weeks (28 days) or longer, then the patient receives an advanced wound care product. Based on the 51 day median time interval between the first patient visit and the start of vCPM treatment, we can assume that the majority of DFUs failed at least GWC alone prior to treatment with vCPM.
We also evaluated whether 50% wound area reduction at week 4 of treatment can predict wound closure by week 12. Such a surrogate marker helps minimize patient exposure to unsuccessful treatment, which has tremendous value for patients, wound care providers and payers. Previously published studies identified wound area reduction at week 4 as a predictive surrogate marker of closure for GWC at later time points. A retrospective cohort study utilizing the Curative Health Services database was conducted by Margolis et al. in 2003 . This study aimed to find a surrogate marker that could predict closure by looking at percent wound area change at 2, 4, and 8 weeks of care. Approximately 40,000 DFUs in 20,000 patients were analyzed, and results showed that the percent change in wound area at 4 weeks of care could correctly predict wounds that healed versus wounds that failed to heal by week 20. 34 In the same year, Sheehan et al. reported that percent change in wound area of DFUs over a 4-week period was a robust predictor of complete healing in a 12-week prospective trial. 35 In a post hoc analysis of 203 patients from a multicenter RCT that compared a collagen/oxidized regenerated cellulose dressing (Promogran; Ethicon, Somerville, NJ) to moistened gauze in the management of DFU, the results showed that subjects with wound area reduction (WAR) greater than the 4-week median (53%) had a 12-week healing rate of 58%, whereas patients with WAR < 4-week median had a healing rate of only 9% (p 5 0.01). Since then, two studies confirmed that 50% WAR after 4 weeks of GWC is a reliable indicator of wound healing. In one study, a single center cohort of 704 consecutive diabetic patients was evaluated, 36 and in a second study, a post hoc analysis of control DFU treatment outcomes from two published RCTs was performed. 37 As such, it is widely accepted to utilize this 4-week time point to identify patients who may not respond to GWC and may require additional treatments.
Interestingly, 50% DFU area reduction at week 4 was not recommended as a predictor of outcome for AWCPs. 35 This statement is based on the fact that the time required for cell proliferation and formation of new tissue, such as blood vessels, is relatively fixed and cannot be easily manipulated. Sheehan et al. stated that AWCPs should support wound closure by sustaining a normal physiological healing rate over time. Therefore, Sheehan et al. concluded that the change in wound area for GWC and AWCPs might be the same by week 4, but AWCPs are more effective than GWC in promoting complete wound closure in DFUs. 35 To the best of our knowledge, we show for the first time that 50% wound size reduction at 4 weeks in the real world setting predicts closure in patients treated with an AWCP. The vCPM RCT showed that both proportions, the > 50% WAR by week 4 and complete closure by week 12, were higher for vCPM compared to GWC. 20 In this retrospective study of 350 patients with DFUs, we found that if a patient had a 50% reduction in wound size by week 4, the probability of closure by week 12 was 77.8% (95% CI 70.8-83.9). If a patient did not show such reduction, the probability of closure by week 12 was only 22.5% (95% CI 16.6-29.5). Results in Table 5 show that this correlation is independent of wound size. Although normal physiological wound closure rates should remain the same for both GWC and AWCPs, it is reasonable to assume AWCPs should have a higher potential to regulate the chronic DFU microenvironment. This alteration should lead to a higher number of wounds with > 50% WAR versus GWC by week 4. Based on this assumption, the 50% wound area reduction by week 4 predictor might also function as a tool for treatment outcomes of advanced wound care modalities. Additional studies are required to validate 50% DFU area reduction by week 4 as a predictive marker for vCPM and other AWCPs.
As with any study, there are limitations that merit discussion. The most obvious limitation is the retrospective nature and absence of a control cohort in this study, which relied on a large database. Lack of a standardized treatment algorithm and treatment selection bias are known limitations of observational studies. The data obtained are only as good as the data recorded, thus potentially introducing measurement error. Measurement error occurs when any measurement about a subject is not accurate. The methods and tools used to measure wounds, define infection, or define "healing" may be systematically different among the centers that participated in the study. Selection bias is also a possibility since patients in our cohort were more likely to have insurance or the resources that could pay for this therapy or adjunctive therapies that make AWCPs more effective.
Despite these limitations, this study found the vCPM in the real world setting confirms vCPM benefits for DFU management and supplements the RCT data. This information can aid policy and treatment decisions regarding advanced wound care technology in the management of diabetic patients with chronic foot ulcers. This study also outlines the importance of future studies to validate 50% wound area reduction as a predictive surrogate marker of closure for vCPM and other advanced wound care modalities.
